MX392605B - Compuestos, composiciones y metodos para el tratamiento de enfermedades. - Google Patents
Compuestos, composiciones y metodos para el tratamiento de enfermedades.Info
- Publication number
- MX392605B MX392605B MX2019000216A MX2019000216A MX392605B MX 392605 B MX392605 B MX 392605B MX 2019000216 A MX2019000216 A MX 2019000216A MX 2019000216 A MX2019000216 A MX 2019000216A MX 392605 B MX392605 B MX 392605B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- compounds
- methods
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000216A MX2019000216A (es) | 2019-11-12 |
| MX392605B true MX392605B (es) | 2025-03-11 |
Family
ID=60913147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000216A MX392605B (es) | 2016-07-06 | 2017-07-06 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
| MX2022006260A MX2022006260A (es) | 2016-07-06 | 2019-01-07 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006260A MX2022006260A (es) | 2016-07-06 | 2019-01-07 | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (enExample) |
| EP (1) | EP3481402A4 (enExample) |
| JP (3) | JP7100227B2 (enExample) |
| KR (1) | KR102569881B1 (enExample) |
| CN (1) | CN109843302B (enExample) |
| AU (1) | AU2017293781B2 (enExample) |
| CA (1) | CA3029644A1 (enExample) |
| IL (1) | IL264049B2 (enExample) |
| MX (2) | MX392605B (enExample) |
| MY (1) | MY199689A (enExample) |
| SG (1) | SG11201811709WA (enExample) |
| TW (1) | TWI689514B (enExample) |
| WO (1) | WO2018009648A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| KR102569881B1 (ko) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| PT3512861T (pt) | 2016-12-01 | 2021-04-29 | Takeda Pharmaceuticals Co | Dinucleotídeos cíclicos |
| WO2018190719A2 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| TWI905974B (zh) | 2018-09-06 | 2025-11-21 | 日商第一三共股份有限公司 | 抗體藥物結合物之用途 |
| WO2020057546A1 (zh) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| CN113348181A (zh) | 2018-10-31 | 2021-09-03 | 诺华股份有限公司 | 包含sting激动剂的dc-sign抗体缀合物 |
| WO2020143740A1 (zh) * | 2019-01-10 | 2020-07-16 | 南开大学 | 环二核苷酸前药分子及其制备方法和应用 |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020267486B2 (en) | 2019-05-09 | 2025-12-18 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as STING modulators |
| JP7622031B2 (ja) | 2019-07-05 | 2025-01-27 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| US20230330248A1 (en) | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| US12589162B2 (en) | 2020-08-07 | 2026-03-31 | Tambo, Inc. | Trans-cyclooctene prodrug of monomethyl auristatin E |
| KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| IL319250A (en) | 2022-08-29 | 2025-04-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including a mutant FC region |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| MXPA05013658A (es) * | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| JP4931798B2 (ja) | 2004-03-15 | 2012-05-16 | ケイ．アール． カラオリス，デイヴィッド | 免疫、炎症または神経保護応答のための方法 |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| NZ702392A (en) | 2012-06-08 | 2017-03-31 | Aduro Biotech | Compositions and methods for cancer immunotherapy |
| EA201590396A1 (ru) | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
| PT2934598T (pt) * | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| WO2014098865A1 (en) * | 2012-12-20 | 2014-06-26 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| WO2014109256A1 (ja) * | 2013-01-09 | 2014-07-17 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| US20140220056A1 (en) | 2013-02-05 | 2014-08-07 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
| ME03586B (me) | 2013-05-18 | 2020-07-20 | Univ California | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon" |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| WO2015185565A1 (en) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| ES2764178T3 (es) * | 2014-12-16 | 2020-06-02 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para inducción de citocinas |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JO3746B1 (ar) * | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| UY36969A (es) | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
| HUE073018T2 (hu) | 2016-01-11 | 2026-01-28 | Innate Tumor Immunity Inc | Ciklikus dinukleotidok állapotok kezelésére, amelyek STING-aktivitással kapcsolatosak, mint például rák |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| WO2017151922A1 (en) | 2016-03-02 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| KR102569881B1 (ko) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| PT3512861T (pt) | 2016-12-01 | 2021-04-29 | Takeda Pharmaceuticals Co | Dinucleotídeos cíclicos |
| AU2017378783A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| AU2017378782A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| JP7591348B2 (ja) | 2017-02-21 | 2024-11-28 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| JP2020524717A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの小分子調節因子 |
| CA3067257A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
-
2017
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active Active
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 MY MYPI2019000212A patent/MY199689A/en unknown
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en not_active Ceased
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 MX MX2019000216A patent/MX392605B/es unknown
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP7749629B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023182645A (ja) | 2023-12-26 |
| WO2018009648A1 (en) | 2018-01-11 |
| SG11201811709WA (en) | 2019-01-30 |
| EP3481402A1 (en) | 2019-05-15 |
| CA3029644A1 (en) | 2018-01-11 |
| AU2017293781A1 (en) | 2019-02-07 |
| IL264049B1 (en) | 2023-07-01 |
| US11033569B2 (en) | 2021-06-15 |
| JP2019532084A (ja) | 2019-11-07 |
| JP7100227B2 (ja) | 2022-07-13 |
| US20220054523A1 (en) | 2022-02-24 |
| TW201805295A (zh) | 2018-02-16 |
| JP7749629B2 (ja) | 2025-10-06 |
| IL264049B2 (en) | 2023-11-01 |
| JP2022106989A (ja) | 2022-07-20 |
| KR102569881B1 (ko) | 2023-08-22 |
| TWI689514B (zh) | 2020-04-01 |
| KR20190032408A (ko) | 2019-03-27 |
| CN109843302B (zh) | 2022-11-29 |
| MY199689A (en) | 2023-11-17 |
| NZ750055A (en) | 2025-08-29 |
| EP3481402A4 (en) | 2020-01-22 |
| IL264049A (en) | 2019-01-31 |
| CN109843302A (zh) | 2019-06-04 |
| US11744845B2 (en) | 2023-09-05 |
| MX2019000216A (es) | 2019-11-12 |
| MX2022006260A (es) | 2022-06-29 |
| AU2017293781B2 (en) | 2022-12-22 |
| US20190262372A1 (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000216A (es) | Compuestos, composiciones y metodos para el tratamiento de enfermedades. | |
| CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
| ECSP21073266A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedad | |
| CO2022002759A2 (es) | Antagonistas de hpk1 y sus usos | |
| CL2018002359A1 (es) | Métodos para usar agonistas de fxr | |
| CL2018001252A1 (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton | |
| CL2018001845A1 (es) | Moduladores de la 5'-nucleotidasa, ecto y su uso | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| MX2024011869A (es) | Anticuerpos anti-tau y metodos de uso | |
| MX2019001672A (es) | Composiciones de poxvirus quiméricos y usos de las mismas. | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CO2018005954A2 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| UY36458A (es) | Anticuerpos humanos para hemaglutinina influenza. | |
| MX373341B (es) | INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS. | |
| CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO2019009787A2 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos | |
| MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| CO2020015747A2 (es) | Analogos de rapamicina y usos de los mismos | |
| CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| MX2017006448A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139). | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| CL2018002023A1 (es) | Uso de moduladores de receptores de gabaa para el tratamiento de picor. |